Respiri Limited (RSH:ASX)

6.8¢

right-arrow Created with Sketch. -0.001 (-1.45%)
MCAP $49.87M
Last trade 15.53pm 20/10/2021 20mins delayed

Latest Announcements

14/10/2021RSHRespiri Limited
27/08/2021RSHRespiri Limited
27/08/2021RSHRespiri Limited
27/08/2021 Price SensitivePSRSHRespiri Limited
05/08/2021RSHRespiri Limited
03/08/2021RSHRespiri Limited
30/07/2021 Price SensitivePSRSHRespiri Limited
29/07/2021RSHRespiri Limited

Company Overview

Respiri Limited is an Australia-based company, engaged in research, development and commercialization of medical devices, and the development of mobile health applications. The Company's segments include Australia and Israel. The Australia segment is engaged in research, development and commercialization of medical devices, and the production of mobile health applications in Australia. The Israel segment is engaged in research, development and commercialization of medical devices, and the production of mobile health applications in Israel. The Company has developed a wheezo, which is an eHealth Saas platform that uses a device and app to measure, record and assist asthma monitoring. Its device and app make up a cloud-based mobile health platform that records wheeze and other clinically relevant symptoms and signs of asthma.

RSH in the news

Respiri (RSH) begins selling its wheezo device across more than 570 pharmacies…
Respiri (RSH) has signed an agreement with TerryWhite Chemmart to sell and…
Respiri (RSH) has received United States Food and Drug Administration (FDA) clearance…
Respiri (RSH) has significantly enhanced the gross margins on the manufacture of…

Search Previous Announcements